About
FidoCure is an AI-enabled personalized medicine platform developed by One Health Company that is transforming how canine cancer is diagnosed and treated. Rather than relying on one-size-fits-all chemotherapy or radiation, FidoCure combines genomic testing with tumor profiling to pinpoint the specific cancer-driving mutations present in each dog's tumor. Based on these insights, its AI recommends targeted therapeutic options tailored to each patient's unique genetic profile, offering a more hopeful prognosis for dogs with cancer. The platform is designed for both veterinarians—who access it through a dedicated clinical portal—and pet parents navigating a cancer diagnosis. Veterinary oncologists and general practitioners can leverage FidoCure's evidence-based recommendations to expand their treatment toolkit and make more informed clinical decisions. FidoCure has sequenced and collected real-world outcome data from thousands of dogs, building the world's largest proprietary canine cancer genomics dataset. This continuously growing database powers the platform's AI and has enabled peer-reviewed research published in leading journals. Studies have demonstrated that precision medicine tools can reduce the risk of death in dogs with aggressive cancers like hemangiosarcoma by up to 50%. FidoCure's work also advances comparative oncology, positioning companion animals as a unique model for developing novel cancer therapeutics that may benefit human medicine as well. It is a groundbreaking intersection of AI, genomics, and veterinary science.
Key Features
- Genomic Tumor Profiling: Sequences canine tumor DNA to identify specific cancer-driving mutations, enabling a precise understanding of each dog's cancer.
- AI-Powered Therapy Recommendations: Matches identified genetic mutations to targeted therapeutic options, going beyond standard chemotherapy and radiation.
- World's Largest Canine Cancer Dataset: Leverages real-world clinico-genomic data from thousands of treated dogs to continuously improve AI recommendations and outcomes.
- Veterinarian Portal: A dedicated clinical interface where veterinary professionals can access genomic reports, case studies, and treatment guidance.
- Published Real-World Evidence: Platform outcomes are validated through peer-reviewed publications in leading veterinary and oncology journals.
Use Cases
- Veterinary oncologists building personalized treatment plans for dogs with aggressive or hard-to-treat cancers
- General practice veterinarians seeking evidence-based targeted therapy options beyond standard chemotherapy and radiation
- Pet owners whose dogs have received a cancer diagnosis and are looking for more effective, personalized treatment alternatives
- Comparative oncology researchers using real-world canine genomic data to identify biomarkers and advance human cancer drug development
- Veterinary clinics aiming to differentiate their oncology services with precision medicine capabilities
Pros
- Precision Medicine Approach: Moves beyond one-size-fits-all treatments by targeting the specific genetic mutations driving each dog's cancer, improving the likelihood of a positive outcome.
- Evidence-Based and Peer-Reviewed: Research published in collaboration with institutions like Tufts University and the Broad Institute of MIT and Harvard validates platform effectiveness.
- Benefits Both Veterinary and Human Medicine: Canine cancer data contributes to comparative oncology research that can accelerate drug development for human patients.
Cons
- Highly Niche Application: FidoCure is exclusively focused on canine cancer treatment and is not applicable to other veterinary conditions, species, or general AI use cases.
- Cost and Accessibility Barriers: Genomic testing and precision targeted therapies can be significantly more expensive than conventional veterinary cancer treatments, limiting access for some pet owners.
- Requires Veterinary Involvement: Pet owners cannot use the platform independently; a licensed veterinarian must be involved in the diagnostic and treatment process.
Frequently Asked Questions
How does FidoCure work?
FidoCure collects a tumor sample from the dog, performs genomic sequencing to identify cancer-driving mutations, and uses AI to recommend personalized targeted therapies. Results are delivered to the veterinarian through the FidoCure portal.
Who can use FidoCure?
FidoCure is designed for licensed veterinarians treating dogs with cancer. Pet parents can also learn about the platform and find participating clinics through the FidoCure website.
What types of canine cancer does FidoCure support?
FidoCure supports a wide range of canine cancers, with published research covering aggressive types like hemangiosarcoma and histiocytic sarcoma. The genomic approach is applicable across many tumor types.
Is FidoCure's effectiveness backed by research?
Yes. FidoCure's outcomes are published in peer-reviewed journals and validated through collaborations with leading research institutions. Studies show precision medicine tools can reduce the risk of death in certain cancers by up to 50%.
How is FidoCure different from standard veterinary cancer treatment?
Standard treatments like chemotherapy and radiation are broad-spectrum approaches. FidoCure uses each dog's unique tumor genomics to identify which specific targeted therapies are most likely to be effective, personalizing treatment rather than applying a generic protocol.
